The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Serotonin syndrome: history and risk
Abstract
Summary—This review focuses on the history of investigations into the behavioural reaction resulting from excess stimulation of postsynaptic 5‐hydroxytryptamine receptors and the relative risk of this occurring with different combinations of drugs. Other aspects, particularly treatment with 5‐hydroxytryptamine receptor antagonists, are reviewed in a recent separate paper [44]. The first human case was in 1955 and animal work had defined the characteristic features by 1958, and established they were lessened by chlorpromazine. Substantial evidence of a ‘dose‐effect’ relationship existed by 1984. The relative risk with different drug combinations is assessed from available evidence and argued to be strongly associated with the degree of elevation of 5‐hydroxytryptamine, which is greatest following combinations of irreversible inhibitors of monoamine oxidase A and B with potent serotonin reuptake inhibitors. The various serotonergic drugs that may be implicated in serotonin syndrome are tabulated and discussed in relation to the relative risk. It is suggested that the proposed ‘diagnostic criteria’ for serotonin syndrome are inappropriate since there is a continuous spectrum from side effects to toxicity. The term ‘serotonin syndrome’ may encourage the presumption that it is an idiosyncratic response, as neuroleptic malignant syndrome is usually considered to be. The terms ‘toxic serotomimetic reaction’ or ‘toxic serotonin syndrome’ may be preferable alternatives. The differences between serotonin syndrome and neuroleptic malignant syndrome are highlighted with examples from difficult or questionable cases in the recent literature. It is proposed that more systematic national collection of toxicity data is essential in order to quantify the relative risk of serotonin syndrome with various combinations of serotonergic drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pharmacological profile of antidepressants and related compounds at human monoamine transporters
Tatsumi, M., Groshan, K., Blakely, R. D., & Richelson, E. (1997) · European Journal of Pharmacology · doi:10.1016/s0014-2999(97)01393-9 · Cited by 939
Cited by
Dunkley, E. J. C., Isbister, G. K., Sibbritt, D., Dawson, A. H., & Whyte, I. M. (2003) · QJM · doi:10.1093/qjmed/hcg109 · Cited by 1,029
Tricyclic antidepressant pharmacology and therapeutic drug interactions updated
Gillman, P. K. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707253 · Cited by 694
Self-citationMonoamine oxidase inhibitors, opioid analgesics and serotonin toxicity
Gillman, P. K. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei210 · Cited by 397
Self-citationHuman psychopharmacology of Ecstasy (MDMA): a review of 15 years of empirical research
Parrott, A. C. (2001) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.351 · Cited by 344
Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity
Parrott, A. C. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00711-0 · Cited by 324
Metadata
- Authors
- Gillman, P.
- Venue
- Fundamental & Clinical Pharmacology
- Publisher
- Wiley
- Published
- 1998-09-10
- Volume
- 12
- Issue
- 5
- Pages
- 482-491
- ISSN
- 0767-3981 (ISSN-L)
- 1472-8206
- OpenAlex
- W2144786010
- Cited by
- 167
- References
- 1
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serotonin syndrome: history and risk. https://app.cochat.ai/papers/10.1111/j.1472-8206.1998.tb00976.x
- The paper
- Gillman, P. (1998). Serotonin syndrome: history and risk. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/j.1472-8206.1998.tb00976.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.